WallStSmart

Brookfield Business Corp (BBUC)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Brookfield Business Corp generates 752% more annual revenue ($27.46B vs $3.22B). WST leads profitability with a 16.9% profit margin vs -0.1%. WST earns a higher WallStSmart Score of 67/100 (B-).

BBUC

Hold

43

out of 100

Grade: D

Growth: 6.0Profit: 5.0Value: 6.7Quality: 5.0

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BBUCUndervalued (+88.8%)

Margin of Safety

+88.8%

Fair Value

$324.96

Current Price

$30.85

$294.11 discount

UndervaluedFair: $324.96Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BBUC1 strengths · Avg: 8.0/10
Price/BookValuation
2.8x8/10

Reasonable price relative to book value

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

BBUC3 concerns · Avg: 2.0/10
Return on EquityProfitability
2.4%3/10

ROE of 2.4% — below average capital efficiency

Revenue GrowthGrowth
-4.5%2/10

Revenue declined 4.5%

Profit MarginProfitability
-0.1%1/10

Currently unprofitable

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : BBUC

The strongest argument for BBUC centers on Price/Book.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : BBUC

The primary concerns for BBUC are Return on Equity, Revenue Growth, Profit Margin.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

BBUC profiles as a turnaround stock while WST is a growth play — different risk/reward profiles.

BBUC carries more volatility with a beta of 1.38 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

BBUC generates stronger free cash flow (78M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 43/100), backed by strong 16.9% margins and 21.0% revenue growth. BBUC offers better value entry with a 88.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brookfield Business Corp

INDUSTRIALS · CONGLOMERATES · USA

Brookfield Business Corporation focuses on healthcare, construction and wastewater services in the United States, Europe, Australia, the United Kingdom, Canada and Brazil. The company is headquartered in New York, New York.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?